Literature DB >> 15955448

Dermal fibroblasts from pseudoxanthoma elasticum patients have raised MMP-2 degradative potential.

Daniela Quaglino1, Luigi Sartor, Spiridione Garbisa, Federica Boraldi, Antonietta Croce, Alberto Passi, Giancarlo De Luca, Roberta Tiozzo, Ivonne Pasquali-Ronchetti.   

Abstract

Cultured fibroblasts from the dermis of normal subjects and of Pseudoxanthoma elasticum (PXE) patients were analysed for enzyme activity, protein and mRNA expression of metalloproteases (MMP-2, MMP-3, MMP-9, MT1-MMP) and of their specific inhibitors (TIMP-1, TIMP-2 and TIMP-3). MMP-3, MMP-9 and TIMP-3 mRNAs and proteins failed to be detected in both the medium and the cell layer of both controls and PXE patients. MMP-2 mRNA was significantly more expressed in PXE than in control cell lines, whereas MT1-MMP, TIMP-1 and TIMP-2 mRNAs appeared unchanged. MMP-2 was significantly higher in the cell extracts from PXE fibroblasts than in control cells, whereas differences were negligible in the cell medium. Data suggest that PXE fibroblasts have an increased proteolytic potential, and that MMP-2 may actively contribute to connective tissue alterations in this genetic disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15955448     DOI: 10.1016/j.bbadis.2004.09.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  Elevated circulating levels of matrix metalloproteinases MMP-2 and MMP-9 in pseudoxanthoma elasticum patients.

Authors:  Ulf Diekmann; Ralf Zarbock; Doris Hendig; Christiane Szliska; Knut Kleesiek; Christian Götting
Journal:  J Mol Med (Berl)       Date:  2009-07-03       Impact factor: 4.599

Review 2.  Pseudoxanthoma elasticum: progress in diagnostics and research towards treatment : Summary of the 2010 PXE International Research Meeting.

Authors:  Jouni Uitto; Lionel Bercovitch; Sharon F Terry; Patrick F Terry
Journal:  Am J Med Genet A       Date:  2011-06-10       Impact factor: 2.802

Review 3.  Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms.

Authors:  Qiaoli Li; Qiujie Jiang; Ellen Pfendner; András Váradi; Jouni Uitto
Journal:  Exp Dermatol       Date:  2008-10-22       Impact factor: 3.960

4.  Verteporfin photodynamic therapy combined with intravitreal triamcinolone for choroidal neovascularization due to angioid streaks.

Authors:  Alfredo Pece; Gaetano Russo; Federico Ricci; Vincenzo Isola; Ugo Introini; Giuseppe Querques
Journal:  Clin Ophthalmol       Date:  2010-06-24

5.  Pseudoxanthoma elasticum is a metabolic disease.

Authors:  Qiujie Jiang; Masayuki Endo; Florian Dibra; Krystle Wang; Jouni Uitto
Journal:  J Invest Dermatol       Date:  2008-08-14       Impact factor: 8.551

6.  Pseudoxanthoma elasticum: molecular genetics and putative pathomechanisms.

Authors:  Jouni Uitto; Qiaoli Li; Qiujie Jiang
Journal:  J Invest Dermatol       Date:  2009-12-24       Impact factor: 8.551

7.  New insights into the pathogenesis of pseudoxanthoma elasticum and related soft tissue calcification disorders by identifying genetic interactions and modifiers.

Authors:  Doris Hendig; Cornelius Knabbe; Christian Götting
Journal:  Front Genet       Date:  2013-06-19       Impact factor: 4.599

Review 8.  The ABCC6 Transporter as a Paradigm for Networking from an Orphan Disease to Complex Disorders.

Authors:  Eva Y G De Vilder; Mohammad Jakir Hosen; Olivier M Vanakker
Journal:  Biomed Res Int       Date:  2015-08-18       Impact factor: 3.411

9.  Changes in dermal fibroblasts from Abcc6(-/-) mice are present before and after the onset of ectopic tissue mineralization.

Authors:  Federica Boraldi; Angelica Bartolomeo; Qiaoli Li; Jouni Uitto; Daniela Quaglino
Journal:  J Invest Dermatol       Date:  2014-02-13       Impact factor: 8.551

10.  Fibroblast involvement in soft connective tissue calcification.

Authors:  Ivonne Ronchetti; Federica Boraldi; Giulia Annovi; Paolo Cianciulli; Daniela Quaglino
Journal:  Front Genet       Date:  2013-03-05       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.